Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)
Others
Ratios

Benitec Biopharma (BNTC) EPS (Weighted Average and Diluted) (2021 - 2025)

Benitec Biopharma's EPS (Weighted Average and Diluted) history spans 5 years, with the latest figure at -$0.24 for Q1 2025.

  • For Q1 2025, EPS (Weighted Average and Diluted) fell 4.35% year-over-year to -$0.24; the TTM value through Mar 2025 reached $1.02, up 111.9%, while the annual FY2024 figure was -$5.51, 60.98% up from the prior year.
  • EPS (Weighted Average and Diluted) for Q1 2025 was -$0.24 at Benitec Biopharma, up from -$0.26 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $1.7 in Q2 2024 and bottomed at -$36.27 in Q2 2022.
  • The 5-year median for EPS (Weighted Average and Diluted) is -$0.76 (2021), against an average of -$3.61.
  • The largest annual shift saw EPS (Weighted Average and Diluted) plummeted 3940.32% in 2022 before it surged 164.15% in 2024.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.59 in 2021, then plummeted by 123.73% to -$1.32 in 2022, then crashed by 100.0% to -$2.64 in 2023, then surged by 90.15% to -$0.26 in 2024, then increased by 7.69% to -$0.24 in 2025.
  • Per Business Quant, the three most recent readings for BNTC's EPS (Weighted Average and Diluted) are -$0.24 (Q1 2025), -$0.26 (Q4 2024), and -$0.18 (Q3 2024).